SIETES :: 92916 citas

Resultados de la búsqueda por INFECCIONES OPORTUNISTAS REFINAR BÚSQUEDA

1.

Muanda FT, Sheehy O, Bérard A. Use of trimethoprim–sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102803]

2.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

3.

Rao K, Young VB, Malani PN. Capsules for fecal microbiota transplantation in recurrent Clostridium difficile infection. The new way forward or a tough pill to swallow?. JAMA 2017;318:1979-80. [Ref.ID 102172]

4.

Anónimo. Idelalisib (?Zydelig®): conclusiones de la revaluación europea de su balance beneficio-riesgo (Recomendaciones del Comité para la Evaluación de Riesgos en Farmacovigilancia Europeo-PRAC). Información para profesionales sanitarios. Categoría: Medicamentos de uso humano, seguridad. Referencia: MUH (FV), 14/2016 . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:1-3. [Ref.ID 100490]

5.

Anónimo. FDA advisory recommends approval of experimental drug to treat Clostridium difficile. DIA Daily 2016:2. [Ref.ID 100401]

6.

Anónimo. Riesgo de reactivación del virus de la hepatitis B en pacientes tratados con imatinib, dasatinib, nilotinib, bosutinib y ponatinib (medicamentos inhibidores de la tirosina quinasa Bcr-Abl) . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:8 de abril. [Ref.ID 100110]

7.

Anónimo. Idelalisib (Zydelig): restricciones temporales de uso para prevenir infecciones graves mientras se realiza la revaluación europea del balance beneficio-riesgo . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:18 de marzo. [Ref.ID 100074]

8.

Villiger PM, Adler S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921-7. [Ref.ID 100073]

9.

Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]

10.

Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]

11.

Andersen NN, Pasternak B, Friis-Moller N, Andersson M, Jess T. Association between tumour necrosis factor-a inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809. [Ref.ID 99191]

12.

Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Méek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-34. [Ref.ID 98811]

13.

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers MED, Stevens-Ayers T, Jerome KR, Leisenring W. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015;162:1-10. [Ref.ID 98728]

14.

Anónimo. Anti-inflammatoires non stéroïdiens: infections graves, fasciites cervicales. Prescrire 2014;34:832-3. [Ref.ID 98465]

15.

Anónimo. Aflibercept (Zaltrap). Prescrire 2014;34:258. [Ref.ID 97436]

16.

Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Well J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-13. [Ref.ID 96585]

17.

Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013;347:13. [Ref.ID 96347]

18.

Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]

19.

Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med 2013;173:924-6. [Ref.ID 95515]

20.

Linos E. Balancing the risks and benefits of rituximab. JAMA Intern Med 2013;173:920-37. [Ref.ID 95510]